Trial design
RECRUITMENT, BLIND
This study was a double blind, Phase III, single centre (University of British Columbia, Vancouver, BC) trial with Canada-wide recruitment, of a randomized, placebo-controlled parallel design with 1:1 experimental allocation and 1-month (m) untreated baseline followed by 3-m on experimental therapy. The trial tested oral micronized progesterone (3 × 100 mg spherical capsules at bedtime daily) versus identical placebo. This RCT was active from January 2012 to April 2017. Results were podium-presented at an international meeting